TenNor Therapeutics, a Chinese biotech focused on anti-bacterial drugs, saw its shares jump 179% on debut in Hong Kong after an IPO oversubscribed 9,000 times. The company is developing rifasutenizol, a novel drug targeting Helicobacter pylori infections linked to stomach ulcers and gastric cancer, with approval expected by end of 2026. Despite cumulative losses over 490 million yuan, investors are betting on the drug's potential to address antibiotic resistance and capture a large market. The IPO raised about HK$598 million, supporting TenNor's late-stage clinical trials and future commercialization efforts.
The National Crime Prevention Council (NCPC) has called on lawmakers to reject the House's Kids Internet and Digital Safety Act (H.R. 7757), criticizing it as insufficient for protecting children online. NCPC argues the bill weakens state powers and ...
Shares of Unusual Machines Inc. (UMAC), where Donald Trump Jr. is a shareholder and board member, surged after reports that the Pentagon is discussing direct financial support and equity stakes in domestic drone manufacturers. The funding talks invol...
REalloys has signed a 15-year agreement to secure 15% of Phase 1 production from the Tanbreez heavy rare earth project in Greenland, one of the largest Western-aligned deposits. This deal strengthens US efforts to reduce dependence on Chinese rare ea...
Lion Group Holding Ltd has signed a Memorandum of Understanding with Meili Capital Management Limited to collaborate on identifying and investing in high-growth sectors such as digital payment infrastructure, tokenization of real-world assets, DePIN,...
TotalEnergies has applied for authorization to build a 1.5 GW offshore wind farm off Normandy, France, marking the country's largest renewable energy project. The €4.5 billion investment aims to generate about 6 TWh annually, enough to power nearly o...
